Yazar "Aluclu U." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients: A prospective, randomised, double-blind, placebo-controlled study
    (SMW supporting association, 2003) Dursun M.; Caliskan M.; Canoruc F.; Aluclu U.; Canoruc N.; Tuzcu A.; Yilmaz S.
    Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with fulminant hepatic failure and chronic liver disease. Its pathogenesis is unclear. One of the factors implicated is enhanced GABA-ergic tone, which is probably related to increased concentrations of cerebral benzodiazepine (BNZ). In the present study, we tested flumazenil, a cerebral BNZ antagonist, in cirrhosis patients with hepatic encephalopathy. Methods: Out of 47 patients, 7 were excluded prior to randomization for various reasons. Twenty patients were included in the flumazenil group and 20 in the placebo group in a prospective, randomized, double-blind, placebo-controlled study. Patients were given flumazenil (1 mg/h, continuous IV infusion) or an equal volume of saline solution for 5 hours. Before and after treatment, portosystemic encephalopathy (PSE) stage and number connection test (NCT) scores were checked every half hour for 5 hours. EEG was recorded 15 minutes before and 1 hour after treatment. Results: While significant improvements were determined in PSE stage and NCT score in the flumazenil group, there were no such improvements in the placebo group. There was no statistically significant difference between pre- and post-treatment EEGs in either group. Conclusion: It was concluded that continuous IV infusion of flumazenil had beneficial and safe effects in the treatment of hepatic encephalopathy patients.
  • [ X ]
    Öğe
    An experimental Staphylococcus aureus meningitis model for investigating induced leptomeningeal and subpial inflammation in rats: A transmission electron microscopy study
    (Maghira and Maas Publications, 2007) Guzel A.; Er U.; Tatli M.; Aluclu U.; Ozekinci T.; Nergiz Y.; Ahishali B.
    Objective: To evaluate leptomeningeal and subpial inflammatory responses of experimental Staphylococcus aureus bacteriemia following intraperitoneal and intravenous applications and to compare the inflammatory reactions in different regions of central nervous-system. Material and Methods: Forty anesthetized rats were divided into four groups equal in number. The rats in group-I were given 1 ml suspension of Staphylococcus aureus intraperitoneally. Group-II was the control group of group I; it was administrated 1 ml 0.9% NaCl in water intraperitoneally. The rats in group-III were given the same amount of bacteria intravenously. Group IV was the control group of the group-III; it was administrated 1 ml 0.9% NaCl solution intravenously. The rats were sacrificed on the 21st day. Inflammatory changes of different regions of the central nervous system were examined under transmission electron microscopy. Statistical analysis was done by using variance analysis, Bonferroni, Tamhane post hoc, Student's t and univariate tests. Results: Thoracic and occipital regions were the most vulnerable zones. Increasing of collagen tissue was the most detected inflammatory change. Conclusion: This experimental model can be used for inducing subpial and leptomeningeal inflammations and it may be developed for investigations of pathogenesis of leptomeningitis during systemic infections. © 2007 Neuroendocrinology Letters.
  • [ X ]
    Öğe
    Vertigo: A complication of interferon therapy in a patient with chronic hepatitis C
    (2000) Goral V.; Meric F.; Aluclu U.; Duzen S.
    The occurrence of vertigo in a 60-year-old male submitted to interferon therapy in the management of chronic hepatitis C would appear to suggest that vertigo could be a side-effect of the drug and that it should be immediately withdrawn in such cases.